# ulcerative colitis (UC) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 48057
- Completion tokens: 16877
- Reasoning tokens: 0
- Total tokens: 64934
- API requests reported: 3
- Elapsed seconds: 132.547
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: OpenAI

---
## Data-quality warning and overall interpretation

The statistical pattern is extremely strong but technically warrants audit: all **100 unique genes** have **FDR ≤ 0.01**, while the input contains **175 retained rows with 43 duplicated genes/probes**. This may reflect a genuinely large UC–control contrast, but it can also be amplified by probe dependence, tissue-composition differences, batch effects, or an overly permissive variance model. The values below are therefore interpreted as **direct cohort associations**, not causal effects or independently replicated findings.

Overall, the colonic mucosa shows a coordinated inflammatory and injury-associated state accompanied by loss of normal absorptive, transport, metabolic, and epithelial-specialization programs. Upregulated **DUOX2/DUOXA2, S100A8, LCN2, CXCL1/CXCL2/CXCL3, CHI3L1, PLA2G2A, PI3, MMP3, and TNC** are consistent with epithelial oxidative defense, innate immune recruitment, and tissue remodeling. In parallel, marked downregulation of **AQP8, AQP7, SLC51A, SLC38A4, SLC16A1, HMGCS2, ABCG2, and related transport/metabolic genes** suggests altered epithelial fluid, nutrient, bile-acid, and energy handling. Increased immunoglobulin transcripts and **CTLA4** indicate an altered immune-cell component, although this cannot be separated from epithelial regulation using bulk mucosal data alone.

The supplied pathway batch reported recurring annotations for **fluid/water transport, carboxylic-acid transport, IL-17 signaling, bile secretion, and rheumatoid arthritis-related inflammatory signaling**. These are contextual annotations, not newly computed enrichment statistics; external statistical validation was not performed.

## Core biological programs

### 1. Innate inflammatory, oxidative-defense, and neutrophil-recruitment program

- **Direction:** Upregulated in UC.
- **Supporting genes:** **DUOX2** (log2FC 4.666, FDR 4.448e-26), **DUOXA2** (2.892, 1.117e-10), **S100A8** (3.799, 4.434e-11), **LCN2** (2.668, 1.373e-21), **CXCL1** (3.456, 1.152e-15), **CXCL2** (2.799, 1.728e-11), **CXCL3** (2.330, 2.506e-11), **PLA2G2A** (1.535, 1.357e-11), **PI3** (2.208, 3.968e-19), and **CHI3L1** (4.590, 3.201e-11).
- **Relevant standardized pathways:** KEGG **IL-17 signaling pathway**; Reactome **chemokine receptor binding**, **neutrophil degranulation**, and inflammatory cytokine signaling; GO **chemotaxis**, **defense response**, and **oxidative-stress-related epithelial defense**.
- **Interpretation:** The simultaneous induction of DUOX2/DUOXA2, antimicrobial or granulocyte-associated genes, and three CXCL chemokines supports an inflamed mucosal environment capable of recruiting and activating neutrophil-like myeloid cells. The CXCL1–CXCL2–CXCL3 group is more persuasive than any single chemokine because it forms a coherent chemokine module.
- **Evidence strength:** **Strong direct transcriptomic association**, supported by pathway annotations and a STRING network centered on CXCR2-related chemokine signaling.
- **Limitations:** Bulk mucosa cannot determine whether the signal originates from epithelial cells, infiltrating neutrophils, macrophages, or several compartments. IL-17 pathway annotation does not establish that IL-17 itself is the upstream driver.

### 2. Loss of epithelial fluid, nutrient, bile-acid, and metabolic transport

- **Direction:** Predominantly downregulated in UC.
- **Supporting genes:** **AQP8** (log2FC −4.417, FDR 1.603e-13), **AQP7** (−2.322, 4.037e-20), **SLC51A** (−3.711, 1.537e-20), **SLC38A4** (−3.067, 4.699e-37), **SLC16A1** (−2.375, 5.825e-21), **ABCG2** (−2.919, 1.112e-10), **SLC23A1** (−2.402, 8.893e-29), **G6PC** (−1.523, 1.921e-17), and **HMGCS2** (−3.445, 1.100e-16).
- **Relevant standardized pathways:** GO **fluid transport**, **water transport**, and **carboxylic-acid transport**; KEGG **bile secretion**; Reactome aquaporin-mediated transport and glycerol transport.
- **Interpretation:** Multiple transporters and epithelial metabolic genes move in the same downward direction, indicating impaired or remodeled absorptive epithelial function. The strong decrease in **AQP8** and reduction of **AQP7** are particularly consistent with altered water and small-solute handling, while **SLC51A**, **ABCG2**, and **HMGCS2** suggest changes in bile-acid/organic-solute transport and epithelial metabolic specialization.
- **Evidence strength:** **Strong direct association**, with coherent GO/Reactome/KEGG contextual support.
- **Limitations:** These genes are also markers of epithelial differentiation and cell-state abundance. Reduced expression may reflect epithelial injury or loss of mature absorptive cells rather than a primary transporter defect.

### 3. Epithelial injury, extracellular-matrix remodeling, and wound-response state

- **Direction:** Upregulated in UC.
- **Supporting genes:** **MMP3** (4.642, 5.399e-14), **TNC** (2.579, 2.506e-11), **TGM2** (1.907, 1.562e-10), **TIMP1** (1.969, 1.810e-17), **PDPN** (2.539, 1.747e-10), **PRRX1** (2.907, 4.349e-16), **SERPINB5** (3.294, 2.575e-17), **CDH3** (2.293, 2.595e-11), and **FILIP1L** (1.864, 1.803e-10).
- **Relevant standardized pathways:** GO **extracellular matrix organization**, **cell adhesion**, and **wound healing**; Reactome extracellular-matrix and integrin-associated processes.
- **Interpretation:** The combination of matrix-associated **TNC**, protease **MMP3**, its inhibitor **TIMP1**, cross-linking enzyme **TGM2**, and stromal/repair-associated **PDPN/PRRX1** is compatible with active mucosal remodeling. The concurrent induction of epithelial structural genes may represent regenerative or metaplastic repair rather than restoration of normal mucosal architecture.
- **Evidence strength:** **Strong direct association** with a biologically coherent remodeling signature; the supplied network records place **TNC, TGM2, and FREM2** in an ITGB1-associated interaction neighborhood.
- **Limitations:** The transcript data do not establish increased protease activity, fibrosis, or irreversible remodeling. TNC and PDPN may also reflect increased stromal-cell representation.

### 4. Altered immune-cell representation and adaptive immune activation

- **Direction:** Upregulated.
- **Supporting genes:** The immunoglobulin-containing feature **LOC100290146|IGHV4-31|IGHM|IGHG1|IGH** (1.891, 3.725e-22), **CTLA4** (2.616, 1.112e-10), **DAPP1** (2.204, 2.850e-14), **CD55** (2.038, 1.117e-10), and **UBD|GABBR1** (2.580, 1.010e-10).
- **Relevant standardized pathways:** GO immune-cell activation and lymphocyte-mediated signaling; Reactome cytokine and immune-receptor signaling. The annotation is less specific than for the inflammatory and transport programs.
- **Interpretation:** Increased immunoglobulin transcripts suggest greater B-cell or plasma-cell contribution, while CTLA4 is compatible with activated or regulatory T-cell populations. DAPP1 supports immune-receptor signaling, but these findings primarily indicate altered immune composition or activation rather than a specific T-cell mechanism.
- **Evidence strength:** **Moderate direct association**, supported by immune and tissue-expression annotations.
- **Limitations:** Immunoglobulin-containing probe features can be difficult to interpret because of rearranged transcripts and mixed cell populations. CTLA4 expression alone cannot distinguish regulatory T cells from other activated T-cell states.

### 5. Loss of differentiated epithelial metabolic specialization

- **Direction:** Downregulated in UC.
- **Supporting genes:** **HMGCS2** (−3.445, FDR 1.100e-16), **GBA3** (−3.002, 4.123e-17), **CYP2B6** (−2.777, 4.178e-13), **CYP2B7P|CYP2B6** (−2.804, 1.014e-17), **LIPC** (−1.574, 1.543e-15), **TAT** (−1.189, 1.932e-11), **G6PC** (−1.523, 1.921e-17), and **ACSF2** (−1.927, 9.784e-13).
- **Relevant standardized pathways:** Reactome metabolic pathways; KEGG lipid, bile-secretion, and central carbon-metabolism annotations where applicable; GO cellular metabolic process.
- **Interpretation:** The broad downward pattern across ketogenesis, xenobiotic/lipid handling, and intermediary metabolism is consistent with reduced mature epithelial metabolic function or a shift toward an injured, proliferative, inflammatory epithelial state.
- **Evidence strength:** **Strong direct directionality across multiple genes**, but the pathway-level interpretation is less specific than the inflammatory signature.
- **Limitations:** Several genes have limited or tissue-context-dependent annotation, and some entries are pseudogenes or composite probe labels. Cell composition, diet, medication, and disease severity could substantially affect this program.

## Key genes and interaction modules

1. **DUOX2–DUOXA2 oxidative-defense module**  
   Both are upregulated: **DUOX2 log2FC 4.666, FDR 4.448e-26**; **DUOXA2 2.892, FDR 1.117e-10**. They are pathway co-members and functionally linked components of epithelial hydrogen-peroxide generation; this is a **functional/regulatory relationship**, not inferred here as a direct physical interaction. Validation should determine whether increased epithelial ROS is protective, damaging, or both.

2. **CXCL1–CXCL2–CXCL3 chemokine module**  
   All are upregulated, with log2FC values of **3.456, 2.799, and 2.330**, respectively. The supplied network evidence connects them to **CXCR2**, and OmniPath-related records also place CXCL1/CXCL2 in ligand–receptor signaling. This is **ligand–receptor pathway/network evidence**, not proof of direct physical interaction among the three chemokines.

3. **S100A8–LCN2–PI3 innate inflammatory module**  
   **S100A8** and **LCN2** are strongly upregulated, as is **PI3**. Their relationship is best described as **co-expression and pathway co-membership in an inflamed mucosal environment**; no direct protein interaction is established by the supplied evidence. This module may reflect neutrophil/myeloid infiltration, epithelial antimicrobial responses, or both.

4. **MMP3–TNC–TIMP1 remodeling module**  
   **MMP3** is markedly upregulated (**log2FC 4.642**), with **TNC** and **TIMP1** also increased. These genes are functionally related through extracellular-matrix turnover and protease–inhibitor balance. The relationship is **pathway co-membership and indirect functional coupling**, not necessarily direct physical interaction.

5. **TGM2–TNC–FREM2–ITGB1 network neighborhood**  
   **TGM2** and **TNC** are upregulated, whereas **FREM2** is downregulated (**−1.138, FDR 3.317e-10**). STRING records identify an ITGB1-associated neighborhood involving these genes. STRING edges should be treated as **database-supported functional or physical association of source-dependent type**, not automatically as direct binding.

6. **AQP8–AQP7 epithelial transport module**  
   Both are downregulated, especially **AQP8** (**−4.417, FDR 1.603e-13**) and **AQP7** (**−2.322, 4.037e-20**). They are **pathway co-members** in aquaporin-mediated transport. Network records involving AQP11/AQP12A are indirect contextual associations; direct interaction was not demonstrated.

7. **SLC51A–ABCG2–ABCB11 transport network**  
   **SLC51A**, **ABCG2**, and **ABCB11** are downregulated. Their common interpretation is **epithelial transport and bile/organic-solute pathway co-membership**, not direct interaction. The direction is consistent with altered epithelial handling of luminal and biliary-related metabolites.

8. **HMGCS2 metabolic-specialization marker**  
   **HMGCS2** is downregulated (**−3.445, FDR 1.100e-16**) and may mark loss of differentiated epithelial metabolic function. Its relationship with G6PC and lipid-handling genes is **metabolic pathway co-membership**, not a direct molecular interaction.

9. **IL1RN–SOCS3–IRAK3 counter-regulatory inflammatory module**  
   **IL1RN** (2.876), **SOCS3** (2.786), and **IRAK3** (1.782) are upregulated. Reactome annotates IL1RN in interleukin-1 and interleukin-10 signaling. These genes may represent **negative-feedback or counter-regulatory responses** to inflammation; the dataset does not establish that they successfully suppress disease activity.

10. **BRINP3 epithelial/homeostatic signal**  
    **BRINP3** is downregulated (**−2.133, FDR 6.953e-12**). A UC-specific literature record reports mucosal underexpression of BRINP3 in UC (PMID **25171508**), which is directionally relevant but is not an independent statistic for this cohort. The relationship to the transport and injury programs is currently **indirect or putative**.

## Validation priorities

### 1. Confirm whether the inflammatory signature is epithelial, myeloid, or mixed  
- **Classification:** Confounding or composition check  
- **Why prioritize:** S100A8, immunoglobulin transcripts, CTLA4, CXCL chemokines, and LCN2 may be strongly affected by immune-cell abundance.  
- **Current evidence:** Direct upregulation of these genes, including **S100A8 log2FC 3.799** and the immunoglobulin feature **1.891**.  
- **External support:** Tissue-expression, immune-network, and disease-association annotations support plausibility but do not resolve cellular origin.  
- **Next step:** Perform single-cell or spatial transcriptomics, or bulk deconvolution combined with histologic neutrophil, B-cell, and epithelial markers; validate by multiplex immunohistochemistry or RNA in situ hybridization.  
- **Conclusion:** **Supported hypothesis**, not established cell-specific mechanism.

### 2. Test the DUOX2/DUOXA2–chemokine inflammatory axis  
- **Classification:** Mechanistic hypothesis  
- **Why prioritize:** DUOX2/DUOXA2 and CXCL1/2/3 form one of the most coherent upregulated inflammatory programs.  
- **Current evidence:** **DUOX2 4.666**, **DUOXA2 2.892**, and CXCL1/2/3 all have very small FDR values.  
- **External support:** Reactome and QuickGO support chemokine activity, chemotaxis, and oxidative-defense functions; the records do not prove causal ordering.  
- **Next step:** Use patient-derived colonic organoids and immune co-culture, measure ROS and chemokine secretion, and perturb DUOX2 or inflammatory cytokine signaling.  
- **Conclusion:** **Supported hypothesis**; causality is not established.

### 3. Validate epithelial barrier and transport failure  
- **Classification:** Biomarker  
- **Why prioritize:** The coordinated decrease in **AQP8, AQP7, SLC51A, SLC38A4, SLC16A1, ABCG2, and HMGCS2** may provide a tissue-state signature of epithelial dysfunction.  
- **Current evidence:** AQP8 is strongly downregulated (**−4.417, FDR 1.603e-13**) and the supplied batch recovered water/fluid and carboxylic-acid transport annotations.  
- **External support:** Reactome and MyGene records support aquaporin-mediated transport; these records are functional annotations rather than disease replication.  
- **Next step:** Confirm protein localization and abundance by immunostaining, assess epithelial permeability and transporter function in organoids or ex vivo tissue, and test association with endoscopic activity and treatment response.  
- **Conclusion:** **Supported hypothesis**, with biomarker utility requiring an independent cohort.

### 4. Determine whether MMP3/TNC/TIMP1 indicates active tissue remodeling  
- **Classification:** Interaction / network hypothesis  
- **Why prioritize:** The module combines strong MMP3 induction with increased TNC, TGM2, PDPN, and TIMP1, suggesting a repair/remodeling environment.  
- **Current evidence:** **MMP3 log2FC 4.642**, **TNC 2.579**, and **TIMP1 1.969**, all with FDR below 3e-11.  
- **External support:** STRING provides an ITGB1-associated neighborhood involving TNC, TGM2, and FREM2, but STRING evidence may combine physical, predicted, and functional associations.  
- **Next step:** Spatially localize these genes to epithelium, fibroblasts, and immune cells; measure active MMP3 protein and matrix turnover rather than transcript abundance alone.  
- **Conclusion:** **Supported hypothesis**, not proof of fibrosis or direct molecular interaction.

### 5. Evaluate a compact UC tissue biomarker panel  
- **Classification:** Biomarker  
- **Why prioritize:** A combined panel may outperform individual genes by representing inflammation and epithelial dysfunction simultaneously. Candidate components include **S100A8, LCN2, MMP3, DUOX2, and AQP8**.  
- **Current evidence:** All are highly significant in the supplied cohort, with both inflammatory upregulation and epithelial transport loss represented.  
- **External support:** A UC biomarker literature record is available (PMID **41029776**), but the supplied context does not provide an independent effect estimate or demonstrate that these exact genes replicate in an independent cohort.  
- **Next step:** Pre-specify the panel, test it in an independent UC-versus-control cohort, and evaluate specificity against Crohn’s disease, infection, and non-IBD inflammation.  
- **Conclusion:** **Exploratory hypothesis**; external statistical validation was not performed.

## Major limitations and alternative explanations

1. **Cellular composition:** Increased neutrophil, myeloid, B-cell, or stromal content could explain part of the upregulated immune and remodeling signal, while loss of mature absorptive epithelial cells could explain many downregulated transport genes. Single-cell/spatial profiling and histologic cell counts are needed.

2. **Disease activity and treatment exposure:** UC severity, ulceration, corticosteroids, biologics, antibiotics, and other medications can alter inflammatory and epithelial transcripts. Clinical metadata stratification and adjustment are essential.

3. **Probe and annotation complexity:** The table contains composite features, pseudogene-like labels, immunoglobulin rearrangement features, unnamed probes, and duplicated genes/probes. Probe-level mapping, transcript annotation, and independent re-analysis from raw data should be checked.

4. **Batch, platform, and statistical-model effects:** The universal significance pattern may reflect strong biology, but also unmodeled batch, paired-sample structure, sample imbalance, or underestimated dispersion. Reassessment of normalization, quality control, principal components, covariates, and effect-size confidence intervals is required.

5. **Association does not establish causation:** The results describe the UC mucosal state relative to healthy controls. They do not show whether inflammatory pathways cause epithelial transport loss, whether transport loss drives inflammation, or whether both result from tissue injury. No independent-cohort statistic was supplied, so pathway recurrence and literature support should not be described as replication or validation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=15, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
